Medtech Talk

Solace Therapeutics CEO Bill Gruber hopes to repeat the successful exit he helped execute when Hologic paid close to $300 million for his previous company Interlace.

Oxford’s Scott Defelice explains how his company and 3D printing will impact medtech.

Geoff Gurtner, MD, managing partner of TauTona Group, is trying to look differently at how Medtech is created, funded and sold.

Analysts Michael Lachman and Larry Haimovich put down their pens and pick up the mics to discuss the more promising ophthalmology technologies.

Mark Leahey of the MDMA explains how a move against patent troll could cut the legs out from Medtech entrepreneurs and VCs dependent upon IP protection.

Hanson Gifford of The Foundry reviews the evolving challenges behind Medtech innovation and shares details on Fire1 and Ardian.

Matt Hermann, Senior Managing Director of Ascension Ventures, details how Pro-viders and Payer-sponsored investment firms have grown into influential investors in health care.

Vivo Capital, fresh off raising $750 million for its eight fund, has effectively strad-dled the Pacific, investing in life sciences in US and China. Managing Partner Chen Yu, MD, shares Vivo’s story and explains how US Medtech start-ups stand to benefit from China’s soar-ing health care sector.

Dennis Wahr, MD, CEO of Holaira Inc. and co-chair of the Medtech In-vesting Conference, says “the best is yet to come” for Medtech and shares his strategy for successful VC fund raising.

Justin Klein, MD, general partner at NEA and co-chair of the Medtech Investing Conference, presented NEA’s views the best opportunities in Medtech.